multiple sclerosis
Conditions
Interventions
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: - For the MS patient group: diagnosis of relapsing remitting MS with clinically or radiologically active disease - 20 to 60 years old - Written informed consent
Exclusion criteria
Exclusion criteria: - Current or recent immunomodulating or immunosuppressive therapy, excluding first-line MS treatment started less than 3 months prior to the PET-scans. - Inability to undergo MRI and PET scan (metal objects in or around the body, claustrophobia or inability to lie still in the scanner) and for the patient group contra-indication for gadolinium administration - Significant immune disease other than MS - (History of) other relevant neurological disease - Known allergy including, but not limited to, hay fever, dust mite allergy and allergies to cats or dogs - Known asthma - History of malignancy - Known significant cardiac disease - Inadequate renal function: creatinine clearance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - To determine whether binding of the P2X7-receptor radioligand [11C]SMW139 in the brain in vivo can discriminate active RRMS patients from healthy controls. - To assess retest variability in regional [11C]SMW139 brain uptake - To evaluate which tracer kinetic method is the most suitable for quantification of [11C]SMW139 binding. | — |
Secondary
| Measure | Time frame |
|---|---|
| - To determine whether [11C]SMW139 binding is increased in T2 hyperintense lesions and T1 gadolinium enhancing on MRI. - To determine whether [11C]SMW139 binding correlates with clinical disability in clinically and/or radiologically active RRMS patients. | — |
Countries
The Netherlands
Outcome results
None listed